A Phase I Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL / SLL
Sign Up to like & getrecommendations! Published in 2019 at "Blood"
DOI: 10.1182/blood-2019-127343
Abstract: Introduction: Duvelisib (DUV), an oral inhibitor of PI3K-δ/γ, and venetoclax (VEN), an oral inhibitor of BCL-2, are both approved for relapsed/refractory (R/R) CLL. We previously found that PI3K-δ inhibition sensitizes CLL cells to ex vivo… read more here.
Keywords: gr3; cll sll; consultancy; research funding ... See more keywords
Elacestrant in various combinations in patients (pts) with estrogen receptor-positive (ER+), HER2-negative (HER2-) locally advanced or metastatic breast cancer (adv/mBC): Preliminary data from ELEVATE, a phase 1b/2, open-label, umbrella study.
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.16_suppl.1069
Abstract: 1069 Background: Endocrine therapy (ET) + CDK4/6i is the mainstay in 1st-line ER+/HER2- mBC; however, resistance to ET arises. De novo resistance mechanisms include alterations in the PI3K/AKT/mTOR or cell cycle pathways; acquired resistance mechanisms… read more here.
Keywords: resistance mechanisms; pts enrolled; her2; gr3 ... See more keywords